Engineering the Future of Drug Development.
One AI platform built from the inside out — purpose-designed for the most complex, regulated, and failure-prone phases of the drug development lifecycle.
9 Out of 10 Drugs Never Reach Patients.
Manufacturing and compliance failures kill programs at clinical stage — and haunt them at commercial scale. This is not a science problem. It is a solvable systems problem. The data is unambiguous: the majority of failures trace directly to Chemistry, Manufacturing, and Controls (CMC) gaps — not to flawed molecules or bad biology.
90%+
IND Holds
Trace directly to CMC failures — not bad science (FDA data)
74%+
FDA Enforcement Actions
Cite operator error at commercial stage (PwC analysis)
$2.6B
Average Cost to Market
Most of it is avoidable manufacturing and compliance spend (Tufts CSDD, 2022)
These are not edge cases. Every number above represents a systemic, recurring failure pattern — and a solvable one.
The Cost of Doing Nothing
Without BioXceed, these are not just risks — they are preventable, high-cost, recurring events that erode timelines, capital, and competitive position at every stage of development.
$1M+ Per Batch Failure
Materials. Labor. Investigation. Without BioXceed: detected after the batch is already lost. With BioXceed: flagged before the failure occurs — keeping product, time, and capital intact.
$3M–$24M Per IND Hold
6–12 months of regulatory consequences. Without BioXceed: CMC gaps discovered at filing. With BioXceed: risks flagged months before IND submission — preserving program timelines.
$50M–$500M Per CRL
$500K–$2M/month burn multiplied by delay. Without BioXceed: compliant on paper, vulnerable in practice. With BioXceed: continuously monitored, auditable, and defensible at every inspection.
The Window Is Open Right Now — and the Data Already Exists
Four forces converged in 2025 to create a once-in-a-decade opportunity. The regulatory framework is being written now. The capital is deploying now. The AI infrastructure cost has dropped to startup-viable.
1
Jan 2025 — FDA Enabled AI in Manufacturing
First-ever draft guidance on AI in regulatory decision-making. Early movers shape the compliance framework being written right now.
2
$370B+ US Biomanufacturing Supercycle
Announced US pharma manufacturing investments over 5 years. Every new facility needs cGMP design intelligence from day one.
3
5–10× Domain AI Outperforms General LLMs
Purpose-built AI beats general models on specialized tasks. Infrastructure cost dropped to startup-viable in 2024.
4
The Training Data Already Exists
Every cGMP process and facility has years of batch records, process data, and compliance documentation — required by regulation, now unlocked by AI.
Why Generic AI Cannot Go Where BioXceed Goes
This is not a close comparison. General-purpose AI — ChatGPT, Grok, Gemini — is structurally unfit for regulated drug manufacturing. Hallucination in a batch record triggers FDA action. A missing audit trail fails Part 11. No generic model can bridge that gap.
BioXceed is not an AI tool bolted onto pharma workflows. It was designed from the inside out — purpose-built for the regulatory, scientific, and operational realities of drug manufacturing.
The BioXceed Platform
Two modules. One shared data layer. The only AI platform covering the full drug development lifecycle — from Process Development through Commercial Manufacturing. Each module is purpose-built, yet deeply integrated, so intelligence compounds across every stage of your program.
BioXceed Engineering
AI-Powered Facility & Process Design
- Replaces A&E firms for ground-up and existing facility design
- 6–12 months of lead time compressed to days
- Multiple design options with trade-off analysis
- Feasibility and capacity studies on demand, 24/7
- Covers: facility design · utilities · P&ID generation · cGMP readiness · process scalability
$3.9B–$5.2B annual US A&E market · 0% AI penetration today
BioXceed Intelligence
AI-Powered CMC Compliance & Manufacturing Intelligence
- Operates upstream and alongside your QMS — never touches validated systems
- Predicts failures before they become deviations
- AI companion for PD scientists from day one
- Covers: PD Companion · CMC risk intelligence · CMC compliance · Predictive facility and asset intelligence · MSAT · Scale-up · virtual facility and monitoring
Your QMS records what already happened. BioXceed predicts what's about to happen.